The IPO market pumped the brakes in the shortened holiday week, with six IPOs raising $1.9 billion and just two SPACs raising $300 million. Pipeline activity slowed from previous weeks as well, with six IPOs and seven SPACs submitting initial filings. ...read more
Achilles Therapeutics, a Phase 1/2 biotech developing precision T cell therapies for solid tumors, raised $176 million by offering 9.8 million ADSs at $18, within the range of $17 to $19. The company's pipeline contains cNeT candidate ATL001, which is...read more
Following some turbulence in the IPO market, eight IPOs are scheduled to raise $3.0 billion in the shortened holiday week. Online real estate brokerage Compass (COMP) plans to raise $882 million at a $12.5 billion market cap. Compass...read more
Achilles Therapeutics, a Phase 1/2 biotech developing precision T cell therapies for solid tumors, announced terms for its IPO on Thursday.
The London, UK-based company plans to raise $176 million by offering 9.8 million ADSs at a price range of $17 to $19....read more
US IPO Weekly Recap: The IPO market slows with 6 IPOs in the shortened holiday week
The IPO market pumped the brakes in the shortened holiday week, with six IPOs raising $1.9 billion and just two SPACs raising $300 million. Pipeline activity slowed from previous weeks as well, with six IPOs and seven SPACs submitting initial filings. ...read more
UK-based biotech Achilles Therapeutics prices US IPO at $18 midpoint
Achilles Therapeutics, a Phase 1/2 biotech developing precision T cell therapies for solid tumors, raised $176 million by offering 9.8 million ADSs at $18, within the range of $17 to $19. The company's pipeline contains cNeT candidate ATL001, which is...read more
US IPO Week Ahead: Online real estate and low-cost airlines lead an 8 IPO week
Following some turbulence in the IPO market, eight IPOs are scheduled to raise $3.0 billion in the shortened holiday week. Online real estate brokerage Compass (COMP) plans to raise $882 million at a $12.5 billion market cap. Compass...read more
UK-based biotech Achilles Therapeutics sets terms for $176 million US IPO
Achilles Therapeutics, a Phase 1/2 biotech developing precision T cell therapies for solid tumors, announced terms for its IPO on Thursday. The London, UK-based company plans to raise $176 million by offering 9.8 million ADSs at a price range of $17 to $19....read more